Phase 2 Advanced Breast Cancer Clinical Trials
46 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 46 trials
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 2
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
Advanced Breast Cancer
Henan Cancer Hospital92 enrolled1 locationNCT07540533
Recruiting
Phase 1Phase 2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Metastatic Breast CancerAdvanced Breast Cancer
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerAdvanced Breast Carcinoma
MedSIR200 enrolled56 locationsNCT06486883
Recruiting
Phase 2
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
National Cancer Centre, Singapore40 enrolled1 locationNCT05286437
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 2
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute87 enrolled1 locationNCT06595563
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Advanced Breast Cancer
Dartmouth-Hitchcock Medical Center135 enrolled1 locationNCT05933395
Recruiting
Phase 1Phase 2
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Phase 2
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University45 enrolled1 locationNCT07037199
Recruiting
Phase 2
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Reshma L. Mahtani, D.O.75 enrolled3 locationsNCT06263543
Recruiting
Phase 2
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris139 enrolled11 locationsNCT04965766
Recruiting
Phase 2
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo120 enrolled2 locationsNCT07285382
Recruiting
Phase 2
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER400 enrolled1 locationNCT07259226
Recruiting
Phase 2
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Advanced Breast Cancer
Seoul National University Hospital180 enrolled1 locationNCT05530057
Recruiting
Phase 2
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin186 enrolled1 locationNCT07180082